Genzyme dumps Cerezyme material

To minimize risk to its newly cleaned manufacturing plant and to ensure that new supplies of the Gaucher-disease treatment Cerezyme will be available by the end of this year, Genzyme is discarding some 80 percent of the remaining in-process material. "We could not take the risk of processing material that has any possibility of re-contaminating the plant and setting back our ability to supply Cerezyme," says CEO Henri Termeer, in a statement. The company expects to begin releasing new material in November. Release

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.